Michael A. Narachi
2012
In 2012, Michael A. Narachi earned a total compensation of $2.9M as President, Chief Executive Officer and Member of the Board of Directors at Orexigen Therapeutics, a 50% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $585,938 |
|---|---|
| Option Awards | $1,686,330 |
| Salary | $625,000 |
| Other | $7,776 |
| Total | $2,905,044 |
Narachi received $1.7M in option awards, accounting for 58% of the total pay in 2012.
Narachi also received $585.9K in non-equity incentive plan, $625K in salary and $7.8K in other compensation.
Rankings
In 2012, Michael A. Narachi's compensation ranked 2,400th out of 11,487 executives tracked by ExecPay. In other words, Narachi earned more than 79.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,400 out of 11,487 | 79th |
Division Manufacturing | 831 out of 4,253 | 81st |
Major group Chemicals And Allied Products | 184 out of 1,198 | 85th |
Industry group Drugs | 106 out of 920 | 89th |
Industry Pharmaceutical Preparations | 86 out of 700 | 88th |
Source: SEC filing on April 22, 2015.
Narachi's colleagues
We found four more compensation records of executives who worked with Michael A. Narachi at Orexigen Therapeutics in 2012.
2012
Preston Klassen
Orexigen Therapeutics
Head of Global Contrave Program and Executive Vice President, Product Development
2012
Joseph Hagan
Orexigen Therapeutics
Chief Business and Financial Officer
2012
Heather Turner
Orexigen Therapeutics
General Counsel
2012
Mark Booth
Orexigen Therapeutics